SWP
ZYNE

Stratos Wealth Partners’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Stratos Wealth Partners’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-189
Closed -$2K – 2661
2018
Q3 		$2K Buy
+189
New +$1.45K ﹤0.01% 2757
2018
Q2 		– Sell
-189
Closed -$2K – 2748
2018
Q1 		$2K Buy
+189
New +$2.04K ﹤0.01% 2916

Other funds holding ZYNE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Campbell Capital Management Miami, Florida $279M AUM 49.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Stratos Wealth Partners's ZYNE Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2018, closing a stake of 189 shares — an estimated $2K sold.

Stratos Wealth Partners first reported a position in ZYNE in Q1 2018 and held it in 2 quarters. The position peaked at $2K in Q3 2018. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2018.

  • Stratos Wealth Partners reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 189 Zynerba Pharmaceuticals, Inc shares in Q4 2018, an estimated $2K.
  • Stratos Wealth Partners first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2018 and held it in 2 quarters.
  • Stratos Wealth Partners's Zynerba Pharmaceuticals, Inc position peaked at $2K in Q3 2018.
  • 62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.